Michael R. Jaff

Operational Partner at Gilde Healthcare

Michael R. Jaff, DO is the Chief Medical Officer and Vice-President of clinical affairs, technology and innovation at Boston Scientific Corporation. A professor of medicine at Harvard Medical School, Dr. Jaff was the President of Newton-Wellesley Hospital from October 2016-December 2019. Prior to that, Dr. Jaff was the inaugural Paul and Phyllis Fireman Endowed Chair of Vascular Medicine and Medical Director of the Fireman Vascular Center at the Massachusetts General Hospital. He is an expert in all aspects of vascular medicine, including peripheral artery disease, venous thromboembolic disease, aneurysmal diseases, and all diagnostic strategies in vascular medicine.

He is the founder of VasCore, the Vascular Ultrasound Core Laboratory, the largest of its’ kind in the United States. VasCore has participated in trial design and independent analysis of vascular laboratory images for over 200 prospective multicenter peripheral vascular device and pharmaceutical trials across 66 countries.

Dr. Jaff has published extensively in the field of Vascular Medicine with over 300 peer-reviewed publications and 10 textbooks, is the Past-President of the Society for Vascular

Medicine and Biology and was the first physician to have received the designation as Master of the Society for Vascular Medicine. He is a Fellow of the American College of Physicians, American College of Cardiology, the American Heart Association, and the Society for Cardiovascular Angiography and Intervention, and is a registered physician in vascular interpretation (RPVI).

In November 2011, Dr. Jaff became an alumnus of Harvard Business School after completing the General Management Program.

Location

Delray Beach, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Gilde Healthcare

2 followers

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. Their lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Netherlands, Belgium, and Germany.


Employees

11-50

Links